Abstract: TH-PO236
Trends of Blood Pressure Control in CKD Among US Adults: Findings from the National Health and Nutrition Examination Survey 2011-2020
Session Information
- Hypertension and CVD: Clinical - I
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1602 Hypertension and CVD: Clinical
Authors
- Akbari, Sadaf, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
- Ten Eyck, Patrick, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
- Yamada, Masaaki, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
- Wendt, Linder, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
- Boucher, Robert E., University of Utah Hospital, Salt Lake City, Utah, United States
- Beddhu, Srinivasan, University of Utah Health, Salt Lake City, Utah, United States
- Jalal, Diana I., University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
Background
Hypertension contributes to kidney disease progression, cardiovascular disease, and death in patients with chronic kidney disease (CKD). The evidence and clinical guidelines support lowering blood pressure (BP) goals in this patient population. We evaluated if BP control improved among US adults with CKD.
Methods
In the National Health and Nutrition Examination Survey (NHANES) for the periods 2011-2014, 2015-2016, and 2017-2020, we identified individuals with CKD defined as estimated glomerular filtration rate 20-59 mL/min/1.73 m2 or urinary albumin/creatinine ratio ≥30 mg/g. The following systolic BP categories were evaluated: <120, 120-129, 130-139, and ≥140 mm Hg. All measures were tested for differences between year groups accounting for sample strata, clusters, and weights.
Results
During the periods of 2011-2014, 2015-2016, and 2017-2020, the prevalence of CKD was stable at 14, 13, and 13%, respectively (p value=0.4) and among those with CKD, the % of individuals with self-reported hypertension or taking BP medications was 66, 69, and 86%, respectively (p value<.0001). Although the number of BP medications prescribed increased significantly across time (Table), a significant % of individuals with CKD and hypertension had systolic BP 130-139 mm Hg (17%) or ≥140 mm Hg (37%) during the period 2017-2020 (Figure).
Conclusion
The number of individuals with CKD noted to have hypertension has increased significantly over time. Although there has been a significant increase in the number of BP medications prescribed, a considerable number of individuals with CKD still did not meet their BP goal.
Table: Number of individuals with CKD receiving BP medications
Number of BP medications | 2011-2014 | 2015-2016 | 2017-2020 | p value |
0 | 13,240,309 (45) | 13,283,274 (45) | 6,974,905 (18) | <.0001 |
1 | 8,185,798 (28) | 8,043,510 (27) | 13,346,186 (35) | |
2 | 5,304,534 (18) | 6,290,783 (21) | 11,389,885 (30) | |
3+ | 2,764,304 (9) | 2,130,880 (7) | 6,620,570 (17) |
% in systolic BP categories over time
Funding
- Other NIH Support